Viking Therapeutics, Inc.
4 registered trials on this site, 2 active. This page lists the trials this organization is registered as lead sponsor of, for the compounds covered on PeptideBlog.net. It is a registry listing, not an assessment of the company or its products.
Compounds covered
Registered trials
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) NCT07868835 | VK2735 | Phase 3 | Recruiting | Viking Therapeutics, Inc. | 560 | Jul 2028 | Nov 16, 2026 |
| Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) NCT07868939 | VK2735 | Phase 3 | Recruiting | Viking Therapeutics, Inc. | 560 | Oct 2028 | Nov 16, 2026 |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) NCT07104383 | VK2735 | Phase 3 | Active not recruiting | Viking Therapeutics, Inc. | 1,100 | Jul 1, 2027 | Apr 7, 2026 |
| VK2735 for Weight Management Phase 3 NCT07104500 | VK2735 | Phase 3 | Active not recruiting | Viking Therapeutics, Inc. | 4,500 | Jul 1, 2027 | Nov 24, 2025 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. See the full trial tracker.